Intelligence for life

Helping physicians rule out active, acute myocardial ischaemia using Creavo’s MCG technology

Discover how
*For investigational use only not approved for sale

Bringing MCG to the point of care

Corsens® ED is the first cardiac diagnostic device to bring magnetocardiography (MCG) directly to the patient’s bedside.

The greatest challenge of managing patients who present to the emergency department with chest pain is that only 30% are ultimately diagnosed with acute coronary syndrome (ACS)1. The remaining 70% still have to follow the complete chest pain pathway before they can be ruled out.

Creavo’s Corsens® ED can be used as an aid to rule out active, acute myocardial ischaemia in patients presenting to emergency departments with symptoms consistent with those of acute coronary syndrome. This means that patients can quickly move on to the most appropriate care pathway for their needs, relieving pressure on busy emergency departments.

[1] Backus et al. 2011; Rohacek et al. 2012; Six et al. 2012; Backus et al. 2013

See what is being said about Creavo’s MCG technology

Interview: Prof Mark Kearney
Professor Mark Kearney talks about current guidelines and their implications.

Interview: Dr Francis Morris
Dr Francis Morris talks about identifying patients with heart attacks.

Ischaemia

Myocardial ischaemia is a condition where blood flow to the heart is reduced. This causes a lack of oxygen which can lead to a ‘heart attack’. Corsens® aids healthcare professionals in ruling out active Ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome in the emergency department.

Arrhythmia

Arrhythmia is a disruption of the heart’s normal, regular rhythm. Some arrhythmias, particularly those associated with coronary heart disease, may be life threatening and result in sudden cardiac death (SCD). SCD, both in patients with known risk factors and in people who have had no previous symptoms, is a major public health problem. MCG has the potential to help researchers, and ultimately clinicians, identify those most at risk of SCD, resulting in appropriate, life saving treatments. MCG may also prove useful in helping to identify patients most likely to benefit from expensive treatments for both arrhythmias and severe heart failure.

The unique advantages of Creavo’s Magnetocardiography (MCG) Technology

Creavo’s novel magnetocardiography (MCG) technology captures the minute magnetic signals associated with the heart’s electrical activity via a non-invasive scan within a few minutes. The scan results aid healthcare professionals to rule out active Ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome.

The unique advantages of Creavo’s Magnetocardiography (MCG) Technology

Creavo’s novel magnetocardiography (MCG) technology captures the minute magnetic signals associated with the heart’s electrical activity via a non-invasive scan within a few minutes. The scan results aid healthcare professionals to rule out active Ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome.

Research management suite

The Creavo research management suite is a software program that works with the Corsens® platform to provide access to the raw MCG data. This will enable researchers to conduct their own studies using MCG data captured in locations previously restricted due to access, workflow and space limitations.

Research management suite

The Creavo research management suite is a software program that works with the Corsens® platform to provide access to the raw MCG data. This will enable researchers to conduct their own studies using MCG data captured in locations previously restricted due to access, workflow and space limitations.

Latest News

Creavo named one of Yorkshire’s most exciting companies

We are proud to have been named one of the Top 50 most exciting businesses in Yorkshire by Insider. Steve Parker, CEO of Creavo, said “We are pleased to have been acknowledged for our work in developing a device that has the potential to change the future of chest...

An incredible year for Creavo with exciting prospects for 2019

By Steve Parker, Chief Executive Officer It’s been an incredible year for Creavo, as we move ever closer to the commercialisation of Corsens®, the world’s first deployable MCG device with the potential to revolutionise the cardiac triage process, it is more important...